Vascular endothelial growth factor 2
OwnerCraig A. Rosen, Vivian R. Albert +2inventors
InventorsCraig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
Life of this patent
Estimating the term…
Abstract
Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.
Claims60
An isolated polynucleotide encoding a first antibody comprising an amino acid sequence selected from the group consisting of:
- (a) at least one CDR region of a VH domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide;
- (b) at least two CDR regions of a VH domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide;
- (c) at least three CDR regions of a VH domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide;
- (d) at least one CDR region of a VL domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide;
- (e) at least two CDR regions of a VL domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide;
- (f) at least three CDR regions of a VL domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide;
- (g) at least one CDR region of a VL domain and at least one CDR region of a VH domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide;
- (h) at least two CDR regions of a VL domain and at least two CDR regions of a VH domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide;
- and
- (i) at least three CDR regions of a VL domain and at least three CDR regions of a VH domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide.
An isolated antibody comprising an amino acid sequence selected from the group consisting of:
- (a) at least one CDR region of a VH domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide;
- (b) at least two CDR regions of a VH domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide;
- (c) at least three CDR regions of a VH domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide;
- (d) at least one CDR region of a VL domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide;
- (e) at least two CDR regions of a VL domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide;
- (f) at least three CDR regions of a VL domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide;
- (g) at least one CDR region of a VL domain and at least one CDR region of a VH domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide;
- (h) at least two CDR regions of a VL domain and at least two CDR regions of a VH domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide;
- and
- (i) at least three CDR regions of a VL domain and at least three CDR regions of a VH domain of a second antibody that immunospecifically binds to a VEGF-2 polypeptide.
Dependencies are inferred from the claim text.